Home » Sandeep Duttagupta PhD

Sandeep Duttagupta PhD


Sandeep Duttagupta PhD was a Principal at CBPartners.

Connect with Sandeep Duttagupta PhD


Published Articles

STRIMVELIS™ – The Proof Is In The Messaging

In an unprecedented move, the UK's National Institute for Health and Care Excellence (NICE) recently recommended NHS funding of GSK's gene therapy STRIMVELIS™ for an ultra-orphan immunodeficiency disorder ADA-SCID1 – also dubbed the “Bubble Baby Syndrome” priced at EUR 594,000. Given NICE’s resistance to such high per-patient therapy costs, CBPartners investigates how GSK was able to defend the value positioning of the STRIMVELIS™ to NICE.